Trademark: IDEATE IPILIMUMAB DRUG EVALUATION
Put your brand on the blockchain and timestamp its proof of existence at wikitrademarks.io
Mark Identification
IDEATE IPILIMUMAB DRUG EVALUATION
Click here to search for trademarks similar to IDEATE IPILIMUMAB DRUG EVALUATION
Proof of use for IDEATE IPILIMUMAB DRUG EVALUATION
We do not have any records of a proof of use for IDEATE IPILIMUMAB DRUG EVALUATION at this moment.
Click here to add a proof of use for IDEATE IPILIMUMAB DRUG EVALUATION
Possible trademark infringements of IDEATE IPILIMUMAB DRUG EVALUATION
Basic Information about IDEATE IPILIMUMAB DRUG EVALUATION
- Serial Number
- 86337421
- Filing Date
- 15 Jul 2014
- Registration Number
- 4802230
- Registration Date
- 01 Sep 2015
- Mark Drawing Code
- 4
Classifications
Declare the trademark use of IDEATE IPILIMUMAB DRUG EVALUATION on the blockchain with WikiTrademarks.io.
- First use of IDEATE IPILIMUMAB DRUG EVALUATION anywhere
- IDEATE IPILIMUMAB DRUG EVALUATION was first used on 31 May 2013 for the primary classification of goods and services, international, 042 (Computer, scientific & legal)
- First use in commerce
- There is no first use of this trademark in commerce detected yet.
- Status Code
- 2
- International Code
- 042
- US Codes
- 100; 101
Who owns IDEATE IPILIMUMAB DRUG EVALUATION?
1. Bristol-Myers Squibb Company Princeton NJ
2. Bristol-Myers Squibb Company New York NY
3. Bristol-Myers Squibb Company New York NY
Correspondent
- Marilyn F. Kelly
- Bristol-Myers Squibb Company
- P.O. Box 4000
- Trademark Dept., Mailstop D4243
Put your brand on the blockchain and timestamp its proof of existence at Wikitrademarks.io